Q1 2022 results

Amsterdam, April 25, 2022

Philips delivers Q1 sales of EUR 3.9 billion, with good demand driving 5% comparable order intake growth

  • Group sales amounted to EUR 3.9 billion, with a 4% comparable sales decline on the back of 9% comparable sales growth in Q1 2021
  • Comparable order intake increased 5%, driven by the Diagnosis & Treatment businesses and Hospital Patient Monitoring
  • Income from continuing operations amounted to a loss of EUR 152 million, compared to a loss of EUR 34 million in Q1 2021
  • Adjusted EBITA of EUR 243 million, or 6.2% of sales, compared to 9.5% of sales in Q1 2021
  • Operating cash flow was an outflow of EUR 227 million, compared to an inflow of EUR 321 million in Q1 2021
  • Philips provides update on Philips Respironics field action related to specific CPAP, BiPAP and mechanical ventilators
  • Our products and solutions improved the lives of 1.69 billion people worldwide in Q1 2022, an increase of 50 million lives year-on-year. Reflecting our efforts to expand access to care, this figure includes 170 million lives improved in underserved communities, compared to 160 million in Q1 2021. Find out how Philips measures lives improved.
  • At COP 26, Philips announced an ambitious climate action to drive significant reduction of greenhouse gas emissions in our supply chain, aiming to have at least 50% of our suppliers (based on spend) committed to science-based targets for CO2 reduction by 2025. By the end of Q1 2022, 31% of suppliers (based on spend) had committed to such targets.
  • Philips scored highest of all Dutch companies in the 2022 Global RepTrak 100, the annual global RepTrak ranking of companies with the best reputation, taking 14th place.
  • Our circular system portfolio has been renamed Philips Circular Edition systems, emphasizing our state-of-the-art refurbishment and remanufacturing innovations in transforming pre-owned medical equipment into high-quality circular systems.
Strategic partnerships

New long-term strategic partnerships

Philips signed 12 new long-term strategic partnerships in the quarter, including a 10-year agreement with Oulu University Hospital in Finland to deliver the latest Philips Azurion image-guided therapy solutions, as well as maintenance, consultancy and financing services.
Find out more
Hemodynamic measurement

Expansion of capabilities on handheld ultrasound

Philips expanded its leading ultrasound portfolio with advanced hemodynamic measurement capabilities on its handheld ultrasound Lumify, enabling clinicians to quantify blood flow in a wide range of point-of-care diagnostic applications, including cardiology and obstetrics & gynecology.
Radiology Operations Command Center

New partnerships for Radiology Operations Command Center

Philips entered into partnerships with healthcare providers in the UK and Germany to deliver its vendor-neutral Radiology Operations Command Center, which enables remote collaboration between technologists, radiologists and imaging operations teams across multiple sites, to help increase productivity and expand access to MR- and CT-based diagnosis.
Magnetic Resonance Imaging

Continued success for MR portfolio

Building on the market share gain in 2021, Philips MR delivered strong double-digit order intake growth in the quarter, driven by all major product families. Further highlighting the success of its unique helium-free operating MR portfolio, since its launch Philips has installed more than 500 of its Ingenia Ambition MRI systems, which deliver superb image quality and perform MRI exams up to 50% faster.

Successful expansion into interventional oncology

Philips is successfully expanding into interventional oncology with the installation of its innovative lung cancer diagnosis and treatment solution Lung Suite in hospitals in Belgium, France, Israel, and the UK. Based on Philips Azurion, this solution enhances the accuracy of biopsy procedures and provides a therapy option to immediately treat early-stage lung cancer patients.
remote cardiac patient monitoring

Research highlights benefits of remote cardiac monitoring

Underlining the clinical and economic value of remote cardiac patient monitoring, Philips announced new research demonstrating increased atrial fibrillation detection and significant cost savings using Philips’ mobile cardiac outpatient telemetry monitoring. In addition, Philips expanded its remote cardiac monitoring portfolio with a patch-based, clinical-grade ECG to improve patient recruitment, compliance and retention for clinical trials.
Find out more
Male grooming

Completion of global roll-out of innovative shaver

Philips completed the global introduction of its new Philips Shaver S9000 with SkinIQ with its launch in Japan, resulting in accelerated sales growth for this category, and a 4.9 (out of 5) consumer rating and review score within the first month.
Find out more
Oral healthcare

Strong momentum for oral healthcare innovations

Following the successful refresh of its entry-range electric toothbrushes, the launch of the Sonicare 9900 Prestige premium range, and the launch of innovative interdental cleaning devices in 2021, Philips Oral Healthcare recorded strong double-digit comparable sales growth in the quarter, driven by North America and China.

Make sure you receive the latest news from Philips and alerts for upcoming investor events by subscribing via the following link: Receive updates from Philips